Does pioglitazone prevent macrovascular events in patients with type 2 diabetes?

Hiralal, Rajesh; Koo, Karen K. Y.; Gerstein, Hertzel C.
April 2006
CMAJ: Canadian Medical Association Journal;4/11/2006, Vol. 174 Issue 8, p1090
Academic Journal
The article discusses research being done on the use of pioglitazone to prevent macrovascular events in patients with type 2 diabetes. With reference to a study by J. A. Dormandy et al, published in a 2005 issue of the journal "Lancet." Most patients with type 2 diabetes have a myriad of other metabolic and vascular abnormalities. The association of these metabolic disturbances with macrovascular disease is stated. In addition, this article assesses the effectiveness of the drug.


Related Articles

  • Vildagliptin: profile report. Mueller, Tanja; Barkun, Alan N // Drugs & Therapy Perspectives;Mar2007, Vol. 23 Issue 3, p4 

    Adapted and reproduced from Drugs 2006; 66 (15): 1989-2004[1-4]

  • Rimonabant: An Answer to Obesity in Diabetes? Kuritzky, Louis // Internal Medicine Alert;1/15/2007, Vol. 29 Issue 1, p7 

    The article discusses research being done on the effectiveness of rimonabant for obese patients with type 2 diabetes.

  • OPTIMUS-3: Prasugrel bested off-label doses of clopidogrel in small population of patients with type 2 diabetes. Raible, Eric; Rusk, Judy; Southall, Jennifer // Hem/Onc Today;12/10/2009, Vol. 10 Issue 23, p43 

    The article discusses research on the efficacy of a 60-milligram (mg) loading dose and 10-mg maintenance dose of prasugrel against a 600-mg loading dose and 150-mg maintenance dose of clopidogrel in patients with type 2 diabetes and coronary artery disease, presented by Dominick Angiolillo at...

  • Happy brew year!  // Better Homes & Gardens;Jan2012, Vol. 90 Issue 1, p97 

    The article discusses the benefits of drinking coffee including protection against heart disease, type 2 diabetes, and some cancers.

  • People with type 2 diabetes who took the fat-blocking drug Xenical lowered their long-term heart disease risk.  // Environmental Nutrition;Jan2001, Vol. 24 Issue 1, p8 

    Reports on the reduction of the risk for heart disease in people with type 2 diabetes after taking the fat-blocking agent Xenical.

  • Antiosteoporotic Drugs and Incidence of Type 2 Diabetes Mellitus. Kanazawa, Ippei // Calcified Tissue International;Feb2012, Vol. 90 Issue 2, p163 

    No abstract available.

  • Prevalence of the Metabolic Syndrome and Its Components. Ilanne-Parikka, Pirjo; Eriksson, Johan G.; Lindström, Jaana; Hämäläinen, Helena; Keinänen-Kiukaanniemi, Sirkka; Laakso, Mauri; Louheranta, Anne; Mannelin, Marjo; Rastas, Merja; Salminen, Virpi; Aunola, Sirkka; Sundvall, Jouko; Valle, Timo; Lahtela, Jorma; Uusitupa, Matti; Tuomilehto, Jaakko // Diabetes Care;Sep2004, Vol. 27 Issue 9, p2135 

    Presents the study "Prevalence of the Metabolic Syndrome and Its Components." Statistics on the prevalence of type 2 diabetes worldwide; Risk facing subjects with abnormal glucose metabolism; Definition of the metabolic syndrome and its components; Results of the study.

  • The Insulin-sensitizing Role of the Fat Derived Hormone Adiponectin. Heilbronn, L.K.; Smith, S.R.; Ravussin, E. // Current Pharmaceutical Design;Jul2003, Vol. 9 Issue 17, p1411 

    Adiponectin is an insulin-sensitizing hormone whose blood concentration is reduced in obesity and type 2 diabetes. Administration of recombinant adiponectin in rodents increases glucose uptake and increases fat oxidation in muscle, reduces fatty acid uptake and hepatic glucose production in...

  • Ezetimibe, a Potent Cholesterol Absorption Inhibitor, Normalizes Combined Dyslipidemia in Obese Hyperinsulinemic Hamsters. van Heek, Margaret; Austin, Theodore M.; Farley, Constance; Cook, John A.; Tetzloff, Glen G.; Davis, Harry R. // Diabetes;Jun2001, Vol. 50 Issue 6, p1330 

    Examines the role of ezetimibe as a cholesterol absorption inhibitor in normalizing a combined dyslipidemia in obese hyperinsulenemic hamsters. Increase in the ratio of HDL TO LDL after the addition of ezetimide; Elimination of cholesteryl in the liver; Benefits of ezetimibe in type 2 diabetes.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics